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A lack of consistent, evidence-based practices for blood lead testing of children existed in 
a local public health department (LHD). No known blood lead level is safe, and toxicity 
can result in behavioral and cognitive impairments. The purpose of this project was to 
develop and analyze a clinical practice guideline to establish blood lead testing 
procedures in the LHD to improve testing procedures and enhance future testing within 
the jurisdiction. The RE-AIM framework was used to address the reach, effectiveness, 
adoption, implementation, and maintenance of the clinical practice guideline. Five 
experts evaluated the guideline using the Appraisal of Guidelines for Research and 
Evaluation instrument. The assessment results indicated 96.4% agreement across all 
domains. The experts agreed unanimously to recommend adoption of the clinical practice 
guideline. Implementation of the guideline might advance nursing practice and patient 
care in the LHD through incorporation of evidence-based practices. Implementation 
might also lead to early identification of lead-burdened children and may provide the 
opportunity for treatment to mitigate cognitive and behavioral deficits related to lead 
toxicity, thereby improving child health and decreasing related health care costs. 
Engagement of the clinical practice guideline will support positive social change through 
the empowerment of public health nurses to provide optimal care to a population of 
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Section 1: Nature of the Project 
Blood lead testing of children is a procedure that should occur for every child 
(American Academy of Pediatrics, 2017). Elevated levels of lead in the bloodstream can 
have detrimental effects on nearly all systems of the body with symptoms that are often 
unrecognizable (Centers for Disease Control and Prevention [CDC], 2017b). There is no 
known safe level, and a child’s cognitive and behavioral abilities can be impaired with 
low-level blood lead levels (CDC, 2017b). Studies of the effects of elevated blood levels 
have resulted in significant changes to the values accepted as normal per CDC guidelines. 
In 1985, a level of 35 micrograms per deciliter (mcg/dL) or lower was considered 
acceptable (CDC, 1997); however, with advances in technology and assessment of 
children, the acceptable level has been lowered multiple times and currently is 5 mcg/dL 
(CDC, 2017a). Although the reference range for lead toxicity and follow-up evaluations 
have changed, the education of health care professionals has not always progressed, and 
testing procedures have remained mostly unchanged (American Academy of Pediatrics, 
2013; Choate & Polivka, 2000).  
Although federal and state guidelines are in place for health care providers to 
follow regarding categories of children to be tested, the local strategies, education, and 
resources necessary to provide the testing and any necessary follow-up activities are not 
always available. The reporting of elevated blood level is a requirement by state 
guidelines; however, blood lead collection and the documentation steps associated with 
the process or case management activities to guide the care of children with identified 
high-level results are not standardized procedures (Michigan Department of Health & 
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Human Services, 2109). The purpose of this project was to develop a clinical practice 
guideline that would produce an effective and efficient blood lead testing procedure for 
the practice setting. Established procedures for the rural practice setting were evaluated to 
identify areas for improved efficiency. Also, collaboration with local partners were 
analyzed to identify needed areas of improved practice. The early identification of 
children with elevated blood lead levels and the education of staff regarding evidence-
based testing guidelines was the intent of this project. Early identification may result in 
improved cognitive functioning for lead-burdened children, a decrease in health care 
costs associated with the treatment of lead toxicity, and a decrease in societal burden 
associated with lead toxicity. 
The practice setting for this project was a rural, local public health department 
(LHD). The LHD is a jurisdictional health department serving six counties with seven 
clinic locations. Although the administrative staff were consistent throughout the LHD, 
the clinic staff and office designs were different in each of the offices.  
To identify blood lead exposure as early as possible, all children enrolled in 
Medicaid health coverage are required to receive testing at 12 and 24 months of age 
(Michigan Department of Health & Human Services [MDHHS], 2017c). Also, Michigan 
law requires that all children enrolled in the Women, Infant, and Children (WIC) 
supplemental food program are to receive blood lead testing regardless of Medicaid 
enrollment status (MDHHS, 2017c). At the time of the DNP project, there were no 
statewide testing guidelines specific to uninsured or privately insured children in 
Michigan. In the United States, few states require universal lead testing of children at 
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ages 1 and 2 years (Raymond, Wheeler, & Brown, 2014) and Michigan is not one of 
those states. In 2015, 72% of Medicaid-enrolled children in the LHD were tested for 
blood lead (MDHHS, 2017d). Initially, the rate of testing may appear substantial; 
however, when children without Medicaid coverage were included in the data, the 
number of tests completed notably decreased. Lead reporting data for the state of 
Michigan revealed that within the LHD, only 41.8% of all children 1 and 2 years of age 
were tested for blood lead in 2015 (MDHHS, 2017d). These data showed a significant 
gap in testing between children enrolled in Medicaid and those without Medicaid 
coverage. For the lead-burdened child who does not receive testing and remains 
undiagnosed, the long-term effects can be devastating (CDC, 2012). 
Funding levels for blood lead testing have not maintained the same pace as the 
changes associated with increased testing recommendations and lowering of the 
acceptable blood lead level before initiating intensive case management efforts. The State 
of Michigan (2016) reported that funding necessary to meet the current Michigan 
requirements of testing Medicaid enrolled children is insufficient. Although there is a 
state requirement to test all children participating in WIC, the LHD does not currently 
test WIC-enrolled children who are not enrolled in Medicaid because of a lack of 
funding. Several private insurance companies have begun reimbursing for blood lead 
testing, but there are no state or federal requirements to test privately insured children. 
Children without Medicaid or who privately purchased medical coverage have no paid 
options for receiving testing. The mission statement of the LHD focused on the 
promotion of health and well-being through the provision of preventative health care, 
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education, and environmental safety. A lack of funding has hampered efforts to provide 
blood lead testing to all children residing within the jurisdiction.  
Lead toxicity is a quiet and slowly progressing disease process that many people 
disregard, and although most children in the state of Michigan are not burdened with lead 
toxicity, one lead-burdened child is too many. Unlike other services provided within the 
LHD, blood lead testing is not a service that is included in the Michigan Local Public 
Health Accreditation Process (Michigan Public Health Institute, 2017) and has not 
received a great deal of attention within the identified LHD. Other LHD services receive 
program-designated funding and have staff assigned to specific roles. Blood lead testing 
has been a low priority; however, with required testing of all children enrolled in Head 
Start programs, there was a noted need for testing within the LHD. The increased need 
brought focus on established testing procedures of the LHD. Development of updated, 
evidence-based procedures was needed to meet the needs of the organization, nursing 
staff, and children being tested. 
Problem Statement 
The Doctor of Nursing Practice (DNP) project addressed whether evidence and 
theory would support the development of a clinical guideline that would be usable and 
acceptable within the LHD and lead to improved testing within the jurisdiction. 
Development of a clinical practice guideline was facilitated through the collaborative 
efforts of a project team lead by me. The project team used a standardized validation tool 




The LHD lacked evidence-based practices and comprehensive staff training 
related to the blood lead testing of children. Guidelines of LHD procedural development 
were based on the Michigan Medicaid policy requirements and Michigan law, Public Act 
286 of 2006, which states that all children participating in WIC supplemental food 
program are required to receive blood lead testing (MDHHS, 2017c). The developed 
clinical practice guideline was analyzed to establish blood lead testing procedures within 
the LHD and identify improved testing procedures to enhance future testing within the 
jurisdiction. 
The developed guideline focused on consistent blood lead collection practices, 
case management processes for children with identified high levels, increased efficiencies 
of documentation, incorporation of evidence-based practices, expanding services for 
those with private insurance or no medical coverage, and collaboration with community 
partners to secure payment of testing for children without medical coverage. The LHD 
employed outreach workers dedicated to assisting families with medical coverage 
enrollment. This project addressed working collaboratively to discover available 
resources for identified children. Although blood lead testing guidelines were the focus of 
this project, the establishment of health care coverage for all children to receive medical 
care is a national priority. 
The LHD was approached by a local Head Start agency to work collaboratively 
toward increasing blood lead testing. Children enrolled in Head Start are required to 
receive a blood lead test between 36 and 72 months of age if they had not received testing 
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at 12 and 24 months (U.S. Department of Health & Human Services, 2016b). The Head 
Start agency is willing to provide funding for the testing of any student not currently 
enrolled in Medicaid. A partnership between the agencies would promote increased 
testing of children within the jurisdiction and serve as an additional source of data for 
updated testing procedures. 
Staff education regarding blood lead toxicity is necessary to increase awareness 
and testing rates. Choate and Polivka (2000) found that health care provider knowledge 
surrounding established CDC blood lead prevention and testing guidelines was limited 
and providers were most likely to test children who were perceived to be at high risk or 
enrolled in Medicaid. It is not possible to determine a child’s blood lead level based on a 
verbal or visual assessment (CDC, 2015). Polivka, Chaudry, and Sharrock (2009) found a 
27% increase in testing rates of children ages 12 to 72 months following health care 
provider training regarding blood lead toxicity prevention and testing. Education is an 
essential element of advanced nursing practice (American Association of Colleges of 
Nursing [AACN], 2006) and blood lead education is element that may increase testing 
rates within the LHD. 
The practice-focused question that guided this project was the following: Does 
evidence support the development of a process and/or guideline that will lead to future 
consistent blood lead testing procedures within the LHD? Through analysis and 
investigation, I determined how identified gaps in practice could be alleviated by 
designing a new model of care for the LHD to improve the consistency of testing within 
the specified jurisdiction. The evaluation of established procedures used within the LHD 
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was completed, including identifying aspects of care that were successful and 
unsuccessful, analyzing barriers to testing, and identifying testing practices involving 
children who were uninsured or privately insured.  
Focused training of the LHD staff regarding blood lead toxicity, collection 
procedures, and case management strategies would assist in further development of the 
current LHD program. The education of health care providers on lead poisoning 
prevention, lead toxicity, blood lead testing, and case management related to lead toxicity 
has been shown to increase testing rates of children (Polivka et al., 2009). Evidence-
based programs designed for the training needs of health care providers regarding blood 
lead testing are available (Allegheny County Health Department, 2018; CDC, 2004). 
Through evaluation of the procedures and assessment of staffing needs, the most 
appropriate clinical practice guidelines were determined. 
Nature of the Doctoral Project 
Development and planning for quality improvement were accomplished through 
meeting with the LHD nursing director and nursing staff members, as well as 
collaborating with partner agencies to improve testing and education efforts. Statistics 
regarding current levels of testing were retrieved from the LHD, Head Start, and state 
databases. In addition, the procedures of surrounding health departments were assessed 
for identification of successful strategies used in lead testing. 
Sources of evidence that were necessary to address the practice question included 
policies, procedures, and data retrieved from the LHD and CDC, data retrieved from the 
State of Michigan, and information retrieved from agencies collaborating with the LHD 
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on blood lead testing. Also, peer-reviewed articles relating to blood lead testing, quality 
improvement efforts, evidence-based models, and change frameworks were included. The 
creation of evidence-based LHD practice guidelines were achieved through use of 
identified best practices, promotion of patient-centered care, education of nursing staff, 
and involvement of LHD staff members in the development of the project guidelines. The 
purpose of these tasks was to advance staff knowledge, increase testing rates, and ensure 
early identification of lead toxicity. 
Interventions developed to improve projects may not always usable when applied 
in practice. To increase the success of program design, implementation, and evaluation of 
intervention steps, the use of a planning and evaluation framework is necessary (White, 
Dudley-Brown, & Terhaar, 2016). For improvement of the blood lead testing process, the 
model titled Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-
AIM) was utilized. Planas (2008) noted that the RE-AIM model can be used to gauge the 
impact of a public health intervention. The RE-AIM model addresses the dimensions of 
the project reach, effectiveness, adoption, implementation, and maintenance of an 
intervention (King, Glasgow, & Leeman-Castillo, 2010). 
In the current project, the dimension of reach was associated with the 
improvement of child health through a change in testing procedures and the frequency of 
frequency. The dimension of effectiveness was evaluated under the ideal clinic 
environment and evaluated against the quality control of performed tests, documentation, 
billing procedures, and patient notification of testing results. The adoption dimension of 
the model was designed to identify and utilize stakeholders to ensure the project design 
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fit the needs of the target population (see King et al., 2010). The inclusion of staff 
members throughout the development of a procedure increases acceptance of the changes 
(White et al., 2016).  
The dimension of implementation employs standards and guidelines to assess if 
the planned implementation steps were successful and seeks to identify any unanticipated 
barriers (Planas, 2008). Maintenance of the project will be facilitated through the 
consistent engagement of LHD staff members for continuity and efficiency, as well as 
collaboration with the Head Start agency to monitor usage and implications of the 
procedural implementation. 
Significance 
Involvement of stakeholders for any project is vital to success. Involvement of 
crucial participants allows project planners to develop a more comprehensive 
understanding of the culture, provide insight to potential barriers, and increase program 
acceptance through a sense of ownership by the stakeholders (Hodges & Videto, 2011). 
The LHD staff had knowledge and understanding of the organizational circumstances 
that may not have been readily available to the program planner or evident to LHD 
administrative staff. Administrative staff members were able to provide insight into the 
established policy development guidelines, financial status, and collaborative partnership 
potentials concerning blood lead testing. Representatives from the local Head Start 
program provided understanding of barriers of testing within their population of students 
and offered strategies to increase testing in collaboration with the LHD.  
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Through the development of a clinical practice guideline directed at blood lead 
testing, multiple areas of health care may be impacted. Identification of lead-burdened 
children may provide the opportunity for earlier interventions, resulting in improved 
cognition and behavior functions for the child (see State of Michigan, 2016). Nursing 
staff within the LHD may become more knowledgeable regarding blood lead testing. 
Procedures may become more efficient. Successful outcomes may be shared with other 
public health departments and local provider offices offering similar testing capabilities. 
In addition to the positive effects on children, testing and early detection of blood 
toxicity may also have a positive impact from a societal perspective. The State of 
Michigan (2016) estimated the 2014 financial impact of lead toxicity to have been 
approximately $270 million based on the association of decreased earnings, increased 
cost of health care, special education services, and increased levels of crime. 
Furthermore, lead exposure has been associated with 10% of juvenile crimes, $1.33 
million in annual incarceration fees, and an estimated $64.6 million in costs associated 
with adult crimes linked to lead exposure in Michigan (Ecology Center, 2016). Improved 
patient-centered care was the goal of this project, but the potential for significant societal 
gains was also present. 
Summary 
There is not an identified level of blood lead that has been deemed safe (American 
Academy of Pediatrics, 2013). As noted by the CDC (2017a), even a low-level result of 
lead for children can impact their intelligence quotient, decrease their academic 
achievements, and reduce their ability to pay attention. The LHD had blood lead testing 
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procedures in place; however, evidence-based practices were not incorporated into the 
testing guidelines, testing rates for the jurisdiction remained low, and resources for staff 
education were limited.  
Through improved testing procedures, the goal of improving the health of 
children may be obtained. Clinical prevention and population health are essential goals of 
DNP graduates associated with improving overall health status (AACN, 2006). The 




Section 2: Background and Context 
The lack of evidence-based practices (EBP) in established blood lead testing 
procedures within the local health department (LHD) was the practice problem. Current 
testing procedures were developed based on requirements from the Michigan Department 
of Health and Human Services (MDHHS, 2017b) regulations, which state that all 
children enrolled in the WIC supplemental food program and/or Medicaid health 
coverage are required to receive testing at 12 and 24 months of age. The CDC and the 
American Academy of Pediatrics have endorsed universal blood lead testing of all 
children ages 12-36 months (Council on Environmental Health, 2016). However, funding 
for universal testing and associated testing procedures does not exist. In this project, I 
sought to establish clinical practice guidelines for incorporation within the LHD to 
standardize blood lead testing procedures. The practice-focused question that guided this 
process was the following: Does evidence support the development of a process and/or 
guideline that will lead to future consistent blood lead testing procedures within the 
LHD? Established LHD practices were observed, analyzed, and evaluated. I identified 
gaps in LHD practices, identified barriers to testing, and identified standards of practice 
to be used when testing children not enrolled in Medicaid health coverage.  
Educational training for the LHD staff related to updated collection procedures 
may promote increased individual knowledge and the sustainability of EBP integrated 
procedures. Research has shown an increase in the number of children receiving blood 
lead testing as a result of education of providers (Polivka et al., 2009). Education related 
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to the project included information related to lead poisoning prevention, blood lead 
testing, lead toxicity, and case management of lead-toxic children.  
In Section 2, I describe the concepts, models, and theories incorporated in the 
DNP project. The relevance of blood lead testing to nursing practice is presented, as well 
as relevance to the LHD and its coverage area. Finally, I describe my role as the DNP 
student and the DNP project team’s role in this project. 
Frameworks of Use 
The term diffusion was defined by Rogers (2003) as the communication of new 
ideas and interventions through the participants of a specified population. The diffusion 
of innovations (DOI) theory was used throughout the development of this DNP project. 
The DOI theory was designed by Rogers to identify and explain how innovations are 
accepted and used within an identified population (Robinson, 2009). Elements relating to 
the behavior of the diffusion of information throughout a population include the relative 
advantage, compatibility, complexity, trialability, and observability of the proposed 
activity (Sanson-Fisher, 2004). In the current DNP project, the relative advantage was the 
degree to which LHD staff perceived an EBP testing guideline as better than previously 
used practices. Compatibility was to the level of compatibility between the beliefs and 
previous experiences of staff members and the adoption potential of the proposed testing 
procedure. To have an increased potential for adoption, staff members must address an 
issue that is perceived as a current problem in practice (Sanson-Fisher, 2004).  
The complexity of the project related to the staff members’ ability to understand 
and use the clinical procedure. If the procedure is difficult to understand or implement, 
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the potential for sustainable use is greatly diminished (Hodges & Videto, 2011). The next 
element crucial to the DOI theory is the trialability of an innovation. Rogers (2003) 
described trialability of an innovation as the ability of a new idea to be experimented with 
on a partial basis. The approach of a partial adoption allows for participants who are 
uncertain of a complete practice adoption to learn more about the intervention and offer 
feedback throughout the process. The final characteristic associated with the DOI theory 
is the observability of the intervention. Observability refers to the degree of visibility of 
the innovation’s results to participants of the population; the higher the observability of 
the results, the higher the likelihood of innovation adoption (Rogers, 2003).  
Because the LHD is a jurisdiction, consistency between the six counties is 
difficult to achieve. Employing the DOI theory provided me and the DNP project team 
with a framework to share the project innovations throughout the LHD jurisdiction. I 
determined that the DOI approach would assist in the identification of change leaders and 
engagement of staff members who may be reluctant to change. The DOI classifies the 
speed and order of adopters of innovations into five categories: innovators, early 
adopters, early majority, late majority, and laggards (Kaminski, 2011). According to 
Kaminski (2011), innovators require the shortest amount of time and account for 2.5% of 
adopters of innovation, while early adopters (13.5%) are respected opinion leaders and 
role models within a population. The early majority (34%) are agreeable to innovations as 
productivity is enhanced; the late majority (34%) are conservative, cautious, and 
frequently respond to the pressure of their peers to conform; and the laggards (16%) are 
reluctant and suspicious of change and prefer to maintain the status quo (Kaminski, 
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2011). Knowing the different categories of population participants assisted me in 
streamlining project innovations to meet the needs of staff members within each 
category. 
The RE-AIM (2018) framework can be used to assist in the translation of research 
into practice and planning of projects to increase the success rate of adoption when 
placed into practice. There are five steps of translating evidence into action using the RE-
AIM approach. The steps include the reach of the population, effectiveness of the project, 
adoption of the innovation by the target population, implementation, and maintenance of 
the innovation (RE-AIM, 2018). The RE-AIM framework can be used in both the 
designing and planning of programs as well as evaluation of the innovations. For the 
current DNP project, RE-AIM was used throughout the designing and planning process 
while another tool, the Appraisal of Guidelines for Research and Evaluation II instrument 
was used for evaluation purposes. While incorporating the steps of the RE-AIM 
framework, I was guided toward identifying essential project details that would increase 
the rate of adoption, effectiveness, sustainability, and generalizability of the project.  
Concerning the LHD, the reach aspect of the RE-AIM framework included the 
clinical nursing staff and the procedural steps identified to promote engagement with 
nursing staff regarding the DNP project. Efficacy was determined through analysis of the 
innovation outcomes, while adoption addressed those within the LHD participating in the 
interventions. Implementation of the RE-AIM framework focused on ensuring consistent 
and proper delivery of program interventions. Finally, maintenance of the program was 
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determined by the extent to which the innovations were implemented throughout the 
LHD. 
The implementation of a clinical practice guideline may result in a benefit to 
patient care when quality guidelines are used. It was imperative for me to use a 
standardized framework of evaluation to determine the quality of innovations. Analysis 
of the project was completed using the Appraisal of Guidelines for Research and 
Evaluation (AGREE II) instrument of evaluation. The AGREE II instrument is a 23-item 
tool that encompasses the analysis of six domains of quality (Brouwers et al., 2010). Each 
of the six domains includes exclusive quality measures for the developed clinical 
guideline. The AGREE II instrument provides the guidance necessary to conduct a 
thorough evaluation of the developed practice guidelines and the quality of reporting that 
has been identified (Brouwers et al., 2010). Included for use with the AGREE II 
instrument was a user’s manual, which provided guidance to progress through the 
evaluation process with an improved level of confidence. 
Definitions of Terms 
Throughout this doctoral project, specific terms were used interchangeably or 
required a more precise definition. This section includes those definitions.  
Blood lead screening: The process of completing a lead hazard questionnaire with 
a child’s guardian (American Academy of Pediatrics, 2017). 
Blood lead testing: The obtainment of a capillary or venous blood sample to 
assess for lead toxicity (American Academy of Pediatrics, 2017).  
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Parent and guardian: Terms used interchangeably in reference to the adult legally 
responsible for the medical care of a child (State Bar of Michigan, 2017). 
Preschool-aged child: Children 3-5 years of age (CDC, 2017c).  
Relevance to Nursing Practice 
At the time of the study, no level of blood lead had been determined to be safe 
(CDC, 2017b). For that reason, children should receive the recommended blood lead 
testing at 12 and 24 months of age (CDC, 2015). However, more than 500,000 children 
between 1 and 5 years of age in the United States are living with elevated blood lead 
levels (Winslow, 2016). Blood lead testing is a clinical practice that needs increased 
awareness and understanding to combat the potential for damage to the brain and central 
nervous system of children who have been exposed to lead in their environments 
(Nicholson & Cleeton, 2016). One LHD nurse I spoke with regarded blood lead testing as 
an easy process that is postponed to another visit when appointment times are behind or, 
“if the family is unsure, I just skip it because I don’t have time to wait for them to make 
up their minds” (personal communication, December 6, 2017). Through development of 
an evidence-based clinical practice guideline, training, and education, the LHD nurses 
will have the tools necessary to provide optimal preventive care to children in their 
clinics. An evidence-based guideline may serve children throughout their lives by early 
identification of lead toxicity.  
Unless there is an identified risk for exposure, blood lead testing is a procedure 
that is most often completed during preventive health care visits (CDC, 2012). It is during 
these well-child appointments that children also receive immunizations and hemoglobin 
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testing. Parents may be reluctant to have their child receive an additional test due to the 
associated pain or may believe that the child previously received blood lead testing when 
testing did not occur. Polivka, Salesberry, Casavant, Chaudry, and Bush (2006) found 
that among 532 parents surveyed, 56% reported that their child had received testing, but 
only 56% of those children could be confirmed as tested through Medicaid billing claims 
and blood lead laboratory data. This finding demonstrated the lack of understanding on 
behalf of parents and the lack of testing completed during childhood medical 
appointments. 
Another demonstration of testing need was found in Dignam et al.’s (2004) study 
of blood lead testing in targeted, high-risk neighborhoods in Chicago. This study revealed 
that, although the area of testing was deemed as high-risk for lead exposure for children 
living there, 61% of the 539 children tested had never been previously tested, and 27% of 
those tested revealed toxic lead levels (Dignam et al., 2004). Choate and Polivka (2000) 
found that provider knowledge regarding blood lead testing was limited and primarily 
focused on children with Medicaid coverage or those who were perceived to be at 
increased risk of lead exposure. Polivka et al. (2009) found a 27% increase in blood lead 
testing rates among children whose health care provider had received training on blood 
lead toxicity prevention. The provider education program was the Pediatric Lead 
Assessment Network Education Training (PLANET), and was a 1-hour, peer-to-peer 
training that occurred between 2001 and 2006 (Polivka et al., 2009). Awareness and 
education of parents and healthcare providers regarding blood lead toxiciry are critical 
factors for increasing the rate of testing and identification of lead-burdened children 
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(Polivka et al., 2006; Polivka et al., 2009) . Enhanced education on the topic may 
complement efficient and increased testing within the LHD. 
There was limited research available regarding the blood lead testing of children. 
Multiple searches of scholarly databases revealed limited nursing-specific information 
from more than 10 years ago and even fewer from the last 10 years. Polivka (2006) 
sought to identify strategies for use to increase lead-poisoning awareness through public 
health departments, but since that time, additional research has not been done. 
Each U.S. state has specific lead poisoning prevention statutes; however, the 
statutes are not consistent. The State of Michigan maintains laws regarding lead-based 
paint, testing of children enrolled in WIC, a lead abatement program, a Childhood Lead 
Poisoning Prevention Commission, and a Lead in Products Act (Farquhar, 2010). 
Although these statutes are in place, compliance with the guidelines has been shown to be 
deficient (Kemper & Clark, 2005). Kemper and Clark (2005) conducted a random survey 
of primary-care pediatricians in Michigan and found that, although physicians were 
aware of Medicaid testing requirements, 76% reported not routinely performing blood 
lead testing. This reflects poor preventive health care practice and indicates an area in 
which nurses can advocate for more patient testing. 
Although the CDC has encouraged the use of standing orders for blood lead 
testing, implementation is left to the discretion of each state (CDC, 2012). The State of 
Michigan has standing orders in place for the collection of blood lead specimens. Within 
the LHD, standing orders for blood lead testing were in place with the expectation that 
each child 12 to 24 months of age was to receive testing. However, standing orders are 
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not always updated, included in the care of each child, or performed consistently 
throughout an organization. For example, the laboratory collection procedures of the 
State of Michigan are dated as December 2010 and include guidance to conduct a 
diagnostic venous blood collection for all lead levels > 10 mcg/dL (MDHHS, 2018b). A 
blood lead level > 5mcg/dL is required to receive a diagnostic venous collection via 
national standards of practice (CDC, 2017b). 
Development of the DNP project provided a clinical practice guideline to offer 
knowledge and skill training to the nursing staff. Education of nursing staff has been 
shown to increase the rates of blood lead testing overall and case management services 
for lead burdened children (Polivka et al., 2009). In addition to promoting improved 
health for the local community, the project also introduced the incorporation of EBP into 
an organization that has not historically employed EBP with regard to blood lead testing. 
Through project analysis and evaluation, barriers and efficiencies were identified to 
improve patient care within the LHD. The identification of just one child with an elevated 
blood lead level has potential to advance nursing practice within the organization and 
bridge a gap in practice. 
The organization that participated with the DNP project is a six-county 
jurisdictional health department. In 2015, the LHD was responsible for a resident 
population of 188,632; within in the total population, 3,902 were children, aged 12-24 
months (Kidscountdata.org, 2018). According to the Kids Count Data Center (2018), 
1,608 (41.2%) of the children aged 12-24 months residing within the LHD jurisdiction 
received a blood lead test in 2015. The mission statement of the LHD refers to the 
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promotion of health and well-being through the provision of preventative health care, 
education, and environmental safety. Blood lead testing is an area of service that has not 
meeting the minimum expectations set forth by national recommendations nor the 
agency’s mission of care. 
Role of the DNP Student 
As a nurse, I have previously worked within a public health department. I have 
conducted blood lead testing, follow-up testing, education to families, and case 
management of lead-burdened children. Each time I was involved in an elevated lead 
level case, I realized there was a lack of consistency and minimal guidance for providing 
families with current information. It was not until I began the DNP journey that I 
understood the lack of EBP utilization within my previous place of public health 
employment. LHD staffing is limited, and resources are minimal (Citizen’s Research 
Council of Michigan, 2018); the quest to discover new information is often pushed to the 
bottom of the list of tasks to complete.  
In 2010, I worked with the parents of 18 and 36-month old children who were 
severely lead burdened. The parent’s blood test results also revealed elevated lead levels. 
Both children required inpatient chelation therapy. There was no organizational education 
or policy in place to guide my care of this family. I sought resources from surrounding 
LHD’s without success. I turned to resources through the State of Michigan and received 
guidance regarding case management but received limited assistance to identify resources 
available to abate the lead contamination from the family’s dwelling. At the time, I 
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provided the best care that I was capable of to this family, but I realized more resources 
needed to be available for use by public health nurses.  
Looking back on the developmental delays and behavioral issues displayed by the 
two lead-burdened children fuels my desire to improve blood testing procedures. At the 
time of diagnosis, both children were enrolled in Medicaid coverage and attended the 
WIC clinic within the LHD that I worked for, but neither of them had received blood lead 
testing. Testing did not occur until the parents enrolled the 36-month old into a Head 
Start program, where testing is a federal mandate for registration. When the elder child’s 
lead level was determined to be elevated, the younger child was tested with similar 
results. Tragically, these children are living examples of inconsistently administered 
preventative care. I intend to decrease this gap in practice. Conducting the DNP project 
and developing a clinical practice guideline with EBP regarding education and lead 
testing serves as a starting point toward consistent integration of EBP throughout the 
LHD. 
Role of the Project Team 
A project team was established for the development of the DNP project. 
Involvement of stakeholders is crucial to the success of any program through the 
establishment of their requirements and expectations during the planning process (White 
et al., 2016). For this project, the team consisted of two public health nurses, a nurse 
manager responsible for coordination of the lead testing program within the agency, and 
me. Team members assisted me in the development of implementation strategies and 
identification of potential barriers to success. The project team met face-to-face to share 
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background information and EBP regarding blood lead testing. Each LHD member of the 
project team had previous experience with blood lead testing and follow-up care 
associated with elevated results. The project team agreed to collaborate on a bi-weekly 
basis to discuss program planning, implementation status, and evaluation of the project. 
Summary 
As the LHD provided preventative care to residents throughout the jurisdiction, 
the incorporation of education and EBP into blood lead testing procedures were not 
evident. Of concern related to this DNP project was the inconsistency of procedures used 
when testing pre-school aged children for blood lead toxicity. The project utilized the 
diffusion of innovations theory to observe the communication and acceptance process of 
the project throughout the LHD to combat the noted inconsistencies and inefficiencies. 
The RE-AIM framework provided guidance to promote the translation of research into 
practice and the AGREE II instrument was enlisted to evaluate the quality and 
effectiveness of the implemented strategies. Finally, a project team of seasoned public 
health nurses was assembled to guide project development and identify barriers that may 
have had a negative impact on the project outcome. Each of these strategies assisted in 
decreasing identified gaps in practice. 
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Section 3: Methodology 
A local health department (LHD) that lacked evidence-based practice (EBP) 
regarding blood lead testing procedures was the site of this project. The LHD had 
adopted guidelines for testing provided by the Michigan Department of Health and 
Human Services (MDHHS). The MDHHS (2017b) guidelines require all children 
enrolled in Medicaid coverage and/or the Women, Infants, and Children (WIC) 
supplemental food program to be tested at 12 and 24 months of age. Although not all 
entities support universal lead screening of children, the Centers for Disease Control and 
Prevention (CDC) and American Academy of Pediatrics have advocated for universal 
blood lead testing of children (Council on Environmental Health, 2016).  
Existing lead testing practices used by the LHD were observed, analyzed, and 
evaluated to identify potential barriers to testing and deficiencies in LHD practices. The 
practice-focused question that guided the DNP project was the following: Does evidence 
support the development of a process and/or guideline that will lead to future consistent 
blood lead testing procedures within the LHD? I sought to create a clinical practice 
guideline to be incorporated into the LHD processes and standardize testing procedures. 
The incorporation of a clinical practice guideline was intended to expand the knowledge 
base of clinical nursing staff regarding blood lead toxicity, increase the efficiency of 
testing procedures, and increase the number of children tested for blood lead exposure.  
Rogers’s diffusion of innovations (DOI) theory was used throughout the project to 
encourage staff engagement and knowledge of the project status. In addition to the DOI, 
the RE-AIM framework was incorporated to translate identified research into practice 
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and planning of project implementation. The inclusion of the DOI and the RE-AIM 
framework will assist in the successful adoption of interventions (RE-AIM, 2018; 
Rogers, 2003).  
Analysis of the project was completed through the use of the Appraisal of 
Guidelines for Research and Evaluation (AGREE) instrument. The AGREE II instrument 
is a 23-item tool used analyze six domains of quality (Brouwers et al., 2010). This tool 
was of significant value to me as a novice evaluator. Analysis of information gained from 
the AGREE II instrument was critical to advancing the practices within the LHD and 
increasing the opportunity for early identification of children living with the burden of 
lead.  
In Section 3, I describe sources of evidence that were used during the 
development and analysis of the DNP project and steps that were taken to ensure the 
ethical protection of project participants. Presentation of published findings and 
conclusions from previous researchers are shared as well as an overview of data that were 
collected. In addition, I describe the plans for analysis of retrieved information. 
Clarification of Operational Definitions 
The following section provides guidance and clarification of terms used 
throughout the project: 
Blood lead screening: The process of completing a lead hazard questionnaire with 
a child’s guardian (American Academy of Pediatrics, 2017). 
Blood lead testing: Obtainment of a capillary or venous blood sample to assess for 
lead toxicity (American Academy of Pediatrics, 2017).  
26 
 
Parent and guardian: Terms used interchangeably in reference to the adult legally 
responsible for the medical care of a child (State Bar of Michigan, 2017). 
Preschool-aged child: A child 3-5 years of age (CDC, 2017c).  
Sources of Evidence 
Nurses cannot provide quality patient care based solely on clinical experience 
(White et al., 2016). Evidence-based, scholarly resources must be used to ensure that 
safe, effective, and efficient care is delivered with each patient interaction. In the current 
project, multiple resources were used to guide the research associated with the practice-
focused question. At the site of the project, the electronic database of the LHD provided 
procedures used and aggregate data specific to services offered within the organization. 
Patient-specific data were not retrieved.  
The CDC, MDHHS, U.S. Department of Health and Human Services, Agency for 
Healthcare Research and Quality, and the American Public Health Association provided 
evidence on blood lead testing procedures, hazards associated with not using evidence-
based practices, and data necessary to answer the practice-focused question. MDHHS 
information was specific to Michigan, while the other resources offered information that 
was applicable on a broader scale. Each of these resources is readily available to the LHD 
nursing staff; however, at the time of the project, there was no emphasis on EBP 
inclusion within the LHD. 
Assembling material from the sources allowed me to collect evidence to answer 
the practice-focused question and develop a clinical practice guideline for the LHD. The 
Institute of Medicine (2011) defined clinical practice guidelines as “statements that 
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include recommendations intended to optimize patient care that are informed by a 
systematic review of evidence and an assessment of the benefits and harms of alternative 
care options” (p. 1). Development of a clinical practice guideline that is efficient and 
improves patient care requires the review and incorporation of previously established 
evidence. 
Published Outcomes and Research 
A systematic review of literature included a comprehensive search of research and 
critical appraisal of published studies. The strength, consistency, and quality of retrieved 
literature are identified through critical appraisal (White et al., 2014). I conducted a 
systematic review of literature to identify evidence to address the project question.  
The Walden University library served as the primary source for retrieving 
scholarly information. Zotero reference management software was employed to maintain 
an orderly system for document retrieval. Databases and search engines used to identify 
information essential to determining the outcomes of the practice-focused question 
included the following:  
• Cumulative Index to Nursing & Allied Health Literature (CINAHL) 
• Medical Literature Analysis and Retrieval System Online (MEDLINE) 
• Ovid Nursing Journal 
• Cochrane Database of Systematic Reviews 
• ProQuest Nursing & Allied Health Source 
The following key words were used in the database searches: blood lead, blood 
lead testing, blood lead screening, lead toxicity, blood lead toxicity, blood lead 
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guidelines, and blood lead procedures. Searches for nursing-specific research on blood 
lead testing were limited to studies published within the last 10 years. White et al. (2014) 
noted that clinical implementation of research findings frequently takes up to 17 years or 
longer. The initial timeframe for research review was 20 years, but given the limited 
information, the timeframe was expanded to 25 years, including the publication years of 
1993 to 2018. 
Exhaustive literature reviews are comprehensive and include any topic-related 
information (Terry, 2015). Multiple databases and search engines were used to retrieve 
information relevant to the blood lead testing of preschool-aged children. I assumed that 
all pertinent and available resources were reviewed. 
Evidence Generated for the Doctoral Project 
After developing the clinical practice guideline, I invited experts in the field of 
public health nursing and blood lead testing to evaluate the guideline. Ten experts were 
invited via the letter of participation (see Appendix A) with a goal of recruiting five 
participants. Prospective participants met the criteria of having (a) worked in the health 
department for a minimum of 2 years, (b) regularly conducted blood lead testing on 
children, and (c) had experience in case management processes of elevated blood lead 
level results. The age range of invited expert panel members was 30 to 65 years. All races 
and genders were invited to participate. Participants were not members of the DNP 
project team. 
The developed clinical practice guideline was shared with the invited experts. The 
AGREE II instrument was used to guide evaluations of the clinical practice guideline. 
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The invited expert panel was provided with a copy of the AGREE II instrument for 
completion (see Appendix B). A copy of the AGREE II user’s manual was also provided 
to the invited expert panel for reference during the review process. The AGREE II 
instrument was used to assess the quality of the guideline, ensure that potential biases had 
been addressed, confirm that recommendations were internally and externally valid, and 
determine that the guideline was feasible for use in practice (see Brouwers et al., 2010).  
Expert comments and timely return of the completed AGREE II instrument tool 
were requested. Consent was recognized through the contributions received from the 
invited participants. Five responses to the letter of participation were received. 
Confidentiality of the expert panelists’ identities was always maintained. 
Responses received from the expert panel via the AGREE II instrument were 
analyzed to discern the strengths and weaknesses of the proposed clinical practice 
guideline. The project team assisted in the appraisal of the responses to increase the 
reliability of the assessment. Following the analysis process, I incorporated recommended 
changes identified by the expert panelists to prepare the practice guideline for 
dissemination to LHD administrators. 
Protections 
The project team was engaged in the project. In addition, the diffusion of 
innovation (DOI) theory was used to identify change leaders and staff members who 
would potentially be reluctant to embrace change. The DOI theory is used to identify how 
a presented innovation is accepted and applied within an observed population (Robinson, 
2009). The people who will be most impacted by a change process must be informed and 
30 
 
included for outcomes to be successful (Hodges & Videto, 2011); in this case, it was 
necessary for the clinical nursing staff to be aware of the DNP project.  
Support from the agency’s nursing administration was crucial to the success of the 
project. To have changes successfully implemented throughout an organization, 
management must agree with the proposal. Nursing administration received project status 
updates throughout the process. A member of the project team was also a nurse manager; 
inclusion of a manager on the team increased transparency of the project.  
The names of participants and the LHD were not revealed during the project. 
Expert panel participants were provided with the Walden University Disclosure To 
Expert Panelist Form For Anonymous Questionnaires (see Appendix C) before reviewing 
the developed practice guideline and completing the AGREE II instrument. Expert 
participants were provided a hard copy of the developed guideline, the AGREE II 
instrument and user’s manual, and a postage-paid envelope to return the completed tool 
to me anonymously. According to Terry (2015), the Code of Federal Regulations does 
not require written consent for surveys that are not collecting information that identifies 
the participant or damages the reputation of a participant.  
Prior to initiation of the project, I obtained approval of the Walden University 
institutional review board (IRB) (IRB approval 10-22-18-0493273). The role of an IRB is 
to identify the necessary components of a project proposal before approval of the project 
(O’Sullivan, Rassel, Berner, & Taliaferro, 2017). Elements to be identified by the IRB 
include the following: 
• identified risks to humans as minimal, 
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• unbiased selection of participants, 
• documentation of participants’ informed consent, 
• appropriate monitoring of collected data for the safety of participants, and 
• provision of safeguarding the privacy of participants and the confidentiality of 
data obtained (O’Sullivan et al., 2017). 
Following receipt of IRB approval, I implemented the project.  
Analysis of data obtained from the participant evaluation tools is necessary so 
conclusions regarding content can be derived and project implications for the agency 
identified (Terry, 2015). Analysis of survey data was facilitated by the project team. The 
23 questions of the AGREE II instrument were rated by reviewers on a continuum 
ranging from strongly agree to strongly disagree (see White et al., 2016). A numerical 
score was associated with each answer represented in a range of 1 (strongly disagree) to 7 
(strongly agree). Submitted scores were then standardized through comparison of scores 
obtained against the maximum possible score. The final analysis of submissions was used 
to formulate a conclusion and incorporate recommendations of the expert panel regarding 
the guideline’s use. 
Summary 
Blood lead toxicity can lead to long-term, debilitating health effects for children 
(CDC, 2017b). Early identification of lead toxicity can prevent associated health risks; 
however, without a valid testing procedure, lead-burdened children may not be identified 
(CDC, 2017b). The DNP project site did not employ EBP while developing its testing 
procedures. By examining information retrieved through a review of the literature, 
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conducting a survey evaluating the beliefs and attitudes of the nursing staff, and 
analyzing data relevant to the project, I sought to develop a clinical practice guideline 
that would be implemented in the LHD. Following approval of the Walden University 
IRB, I developed the clinical practice guideline, facilitated evaluation of the guideline by 
an expert panel, and prepared the final practice guideline for dissemination to the health 
department administrative team. Implementation of the developed guideline may 
facilitate consistent, evidence-based practice in patient care and promote positive social 
change through early identification of lead-burdened children. 
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Section 4: Findings and Recommendations 
A local health department (LHD) did not consistently incorporate evidence-based 
practices (EBP) into the organization’s procedural guidelines. The LHD lacked EBP in 
local blood lead testing procedures. The Michigan Department of Health and Human 
Services (MDHHS) guidelines for age testing categories were incorporated into the LHD 
procedure; however, consistent implementation of testing throughout the agency was not 
occurring. Employee interpretation and application of established procedures were not 
reliable, resulting in the potential for children to not receive appropriate blood lead 
screening. The practice-focused question guiding the project was the following: Does 
evidence support the development of a process and/or guideline that will guide future 
consistent blood lead testing procedures within the LHD? The question guided analysis of 
existing practices to identify gaps in practice and support the development of a clinical 
practice guideline aimed at decreasing inconsistency of blood lead testing in the LHD.  
Sources of evidence that were used during analysis of established LHD practices 
included LHD policies and procedures, collaborative meetings with the DNP project 
team, MDHHS guidelines, and recommendations of the Centers for Disease Control and 
Prevention (CDC). I conducted in-person meetings and e-mail correspondence with the 
DNP project team to discuss the evidence and current LHD practices. Blood lead testing 
evidence retrieved from the U.S. Department of Health and Human Services, the Agency 
for Healthcare Research and Quality, the American Academy of Pediatrics, and the 
American Public Health Association was used throughout the analysis process.  
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Exhaustive literature reviews were conducted to identify information related to 
the blood lead testing of preschool-aged children. Evidence was appraised in 
collaboration with the DNP project team incorporating the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) system. The GRADE system offers 
a systematic means of evaluating the quality of retrieved evidence and development of 
the strength of a recommendation (GRADE Working Group, 2018). The GRADE system 
facilitated communication between DNP project team members during consideration of 
the retrieved evidence. The developed clinical practice guideline was evaluated by an 
expert panel using the AGREE II instrument. The expert panel analysis indicated that the 
information contained in the clinical practice guideline was thorough, evidence based, 
and appropriate for the intended audience. 
Findings and Implications 
The LHD has had a blood lead testing procedure in place for an extended period. 
However, the policy did not include EBP or receive consistent administration throughout 
the jurisdiction. I sought to advance established practices of the LHD through the 
development of a clinical practice guideline (CPG). The CPG offers a comprehensive, 
systematic, evidence-based approach to blood lead testing to promote patient-centered 
care. Section 4 includes a discussion of findings revealed during the analysis of evidence.  
Michigan offers blood lead information on a state-facilitated website; however, 
the information is limited. This website had been the primary reference for the LHD. The 
DNP project team was unaware of the Michigan Childhood Lead Poisoning and 
Prevention Program website, which offers specific guidelines for the state of Michigan 
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and case management steps. Discovery of this information was essential to the project 
development process. 
Testing Guidelines 
On a national, state, and local level, the recommended age parameters of testing 
were consistent. Guidelines to test children at 12 and 24 months of age were noted within 
the LHD procedures and Medicaid guidelines (see Centers for Medicare & Medicaid 
Services, 2018; MDHHS, 2017a). The guideline of testing a child aged 24 to 72 months 
who had not been previously tested for blood lead was also consistent throughout all 
sources.  
An area of inconsistency within the testing categories was noted regarding 
children who are enrolled in Medicaid and those who do not receive Medicaid coverage. 
Michigan law states that any child participating in the WIC supplemental food program is 
required to receive lead testing (Michigan Legislature, 2018); however, the law also 
states that federal funds provided to administer the WIC program are not to be used for 
blood lead testing. Michigan WIC policy states that children enrolled in the program are 
to be assessed for a history of blood lead testing and then referred elsewhere for testing as 
needed (State of Michigan, 2018c). WIC programs are not mandated to perform the blood 
lead screening within the clinic site.  
Although Michigan law requires children enrolled in WIC to be tested for lead, 
the LHD does not test all children. Any child enrolled in Medicaid is eligible to receive 
testing at the LHD. Children without Medicaid coverage are tested only if the guardian 
agrees to pay directly for the service or if private insurance coverage will cover the cost 
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of the test. Michigan does not require universal testing of children; therefore, the number 
of private insurance companies that cover costs associated with blood lead testing is not 
all-inclusive. Children without medical coverage or the ability to pay are referred to 
identify a private provider willing to conduct the testing. 
Risk Assessment Screening 
Although it is the current standard of care to perform a risk assessment 
questionnaire in clinical settings to determine the potential for lead exposure, these 
questionnaires have been shown to be ineffective at identifying children with a higher 
risk of lead exposure. France, Glitterman, Melinkovich, and Wright (1996) measured the 
results of venous blood lead levels against answers received by clinicians on the lead 
screening questionnaire. Throughout the study, venous level results of < 10 mcg/dL, > 10 
to < 20 mcg/dL, and > 20 mcg/dL had a positive predictive value of the questionnaire of 
57%, 51%, and 3% respectively (France et al., 1996). Similarly, a study in Florida 
indicated that the risk assessment questionnaire had a sensitivity of 26.3% and a 
specificity of 72.2% in predicting blood lead levels greater than 2 mcg/dL (Nicholson & 
Cleeton, 2016). Nicholson and Cleeton (2016) concluded that the risk assessment 
questionnaire is not a useful tool in identifying children at greater risk for lead exposure. 
A systematic review of lead screening questionnaires by Ossiander (2013) indicated that 
“lead screening questionnaires showed a wide range of sensitivity and specificity and 




Numerous studies have indicated a lack of reliability in the use of lead screening 
questionnaires and the ability to predict elevated blood lead levels. The LHD uses a 
questionnaire fashioned after the Michigan Childhood Lead Poisoning and Prevention 
Program (CLPPP) questionnaire, but it is not a verbatim copy of the document. The 
screening questions specific to the MDHSS CLPPP questionnaire are listed in Table 1. 
An area of concern is the lack of an option for “unsure” on the LHD’s questionnaire. 
Including the option of “unsure” would provide caregivers the opportunity to initiate 
discussions related to the question. Also, the child’s guardian completes the risk 
assessment on paper without interacting with the nursing staff. Without a verbal 
completion of the risk assessment, there is no opportunity for the guardian to ask 
questions or for the caregiver to assess whether the guardian can read and understand the 
questions. 
The Michigan CLPPP includes guidance for the risk assessment questionnaire 
stating that if all the questions are answered “no,” the child is likely not at risk for lead 
poisoning; if any questions are answered “yes” or “unsure,” the caregiver should consider 
testing (MDHHS, 2017c). As previously noted, the effectiveness of the risk assessment is 
questionable. Children who have an environmental exposure to lead that is not addressed 
in the questionnaire are left vulnerable to not being identified as lead burdened. Although 
research has shown a higher rate of lead toxicity in children living in lower 
socioeconomic situations, members of minority groups, recent immigrants, or children 
living in older homes (CDC, 2015), these are not the only situations in which a child 




Blood Lead Risk Assessment Questionnaire 
 
Note. Adapted from Michigan Department of Health & Human Services (2017c). 
Area Housing 
Guidelines associated with blood lead screening for children are closely tied to the 
socioeconomic status of the child’s family. The screening questionnaire for blood lead 
testing places emphasis on children living in or frequently visiting houses built before 
1978 or those that were recently remodeled (MDHHS, 2017a). Within the LHD 
jurisdiction, the U.S. Department of Commerce (n.d.) estimated 55.4% of the homes were 
built prior to 1979 (see Table 2). The state of Michigan has not identified the individual 
counties of the LHD as being at increased risk of lead exposure based on the percentage 
of children tested and the number of elevated results; however, it is not clear whether the 
lack of identification of high-risk counties is related to the number of children residing in 
Pediatric Screening Questions  Yes No Unsure 
1. Does the child currently live in a home built before 1950 or 
have they lived in a home built before 1950 in the recent 
past? Do they spend time at or often visit a home built before 
1950? 
   
2. Does the child currently live in a home built before 1978 
that was recently remodeled? Have they lived in or often 
visited a home built before 1978 that was recently remodeled? 
   
3. Does the child have a brother, sister, or playmate with lead 
poisoning? 
   
4. Does the child live with an adult whose job or hobby 
involves lead? 
   
5. Does the child’s caregiver use home remedies that may 
contain lead? 
   
6. Is the child included in a special population group such as 
foreign adoptee, refugee, migrant, or foster child?   
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the county who have not been previously tested. As previously noted, 41.8% of children 
ages 1-2 years living in the LHD were tested for blood lead (MDHHS, 2017c). 
Table 2 
 
Housing Units Within the Local Health Department 
 
Age of housing units Number of units 
Units built prior to 1979 64,843 
Total number of housing units 117,048 
Percent built prior to 1979 55.4% 
 
Note. Adapted from Michigan Department of Health & Human Services (2017b). 
 
Training 
Blood lead specimen collection has a high potential for contamination if proper 
steps are not followed (MDHHS, 2018b). Meticulous cleansing of the collection site and 
proper technique are essential to avoid potential contamination (MDHHS, 2018b). Both 
the CDC and MDHHS provide an opportunity for training related to blood lead testing. 
The MDHHS (2010) has a written collection procedure that is accessible online. The 
CDC (2004) also provided a thorough training video displaying proper technique; 
although the video is older, it remains within the current CDC collection of blood lead 
guidelines. However, this video does not provide specific steps in the use of the point-of-
care analyzer; the video is specific to the collection of samples that are transferred to a 
laboratory for capillary result testing.  
Both the CDC and MDHHS refer health care providers using a point-of-care 
blood analyzer to the manufacturer’s website, Magellan Diagnostics, for further 
instruction. The LHD included the website address to the manufacturer’s website in 
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existing blood lead testing procedures; however, there was no documentation of training 
recorded for individual nurses and no indication of individualized training. 
Magellan Diagnostics offers a free web-based certification course for the point-of-
care analyzer used at the LHD. Completion of this course is not required or encouraged 
through the LHD. The course offers information regarding analyzer setup, completing 
quality control checks, sample collection, sample preparation, and cleaning procedures 
related to the analyzer (Meridian Bioscience, 2018).  
The American Academy of Pediatrics (AAP, 2013) Principles of Lead Screening 
do not provide a step-by-step process of correct collection procedures. The AAP does 
offer guidance that the testing site should be clean and that false positives are common, 
thereby encouraging an elevated capillary result to be followed with venous testing.  
The state of Michigan does not offer training associated with the point-of-care 
analyzers because this is a Clinical Laboratory Improvement Amendments (CLIA) 
waived process, and CLIA is a federal program (State of Michigan, 2018b). CLIA-
waived tests are laboratory processes that can be performed in sites possessing a valid 
CLIA certification, that have a history of good laboratory practices, and that are to 
perform an identified test (i.e. blood lead testing) on clinical specimens in a situation that 
is reliable, timely, and at low risk of producing inaccurate results (State of Michigan, 
2018b). 
Level of Results 
A consistent result of > 5 mcg/dL was noted to be considered an elevated blood 
lead level within LHD current procedures and governing bodies (CDC, 2018; MDHHS, 
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2018a). Of significant note, is that the MDHHS Epidemiology and Population Health 
policy regarding blood lead test results defines an elevated blood lead result as any test 
result of 4.5 mcg/dL or higher for children under 6 years of age (MDHHS, 2018). The 
MDHHS (2018) policy discusses a previous database management system that was only 
able to store blood lead results rounded to the nearest whole number; therefore, test 
results of 4.5 to 4.9 mcg/dL were rounded to 5 mcg/dL and considered to be elevated. 
The database within the Michigan Childhood Lead Poisoning and Prevention Program 
(CLPPP) was updated in 2017 and is now capable of storing unrounded numbers (State of 
Michigan, 2018a). As a result of this database upgrade, MDHHS CLPPP considers any 
test result 4.5 mcg/dL or higher to indicate an elevated blood lead level in children under 
six years of age (MDHHS, 2018).  
The rounding of blood lead results was found to be an inconsistency when 
reporting elevated levels within the LHD. The LHD utilizes a point-of-care testing 
machine that records results to a tenth of a whole number. The established LHD policies 
refer to an elevated level as > 5 mcg/dL and the policies do not include instructions for 
nursing staff to round results of 4.5 to 4.9 mcg/dL to 5.0 mcg/dL. An example of 
potential consequences related to this discrepancy is a result of 4.8 mcg/dL may not be 
reported as an elevated result, leading to prolonged exposure and noteworthy 
ramifications. For a child tested at 12 months of age with results recorded as not elevated, 
the child will not be tested again for a minimum of 12 months. If the child is 24 months 
of age or older and tested with a non-elevated recorded result, the child may never be 




The American Academy of Pediatrics notes that lead screening is most often 
performed by utilizing a capillary specimen (2013). Testing of a capillary sample can be 
completed with the use of filter paper, at a laboratory using an EDTA (ethylenediamine 
tetraacetic acid) tube and specimen container, or with a point-of-care lead analyzer. 
Testing with a capillary specimen increases the risk of environmental contamination; 
therefore, when a capillary specimen reveals an elevated result, a confirmatory venous 
sample should be obtained (AAP, 2013) . It is within the retesting guidelines that 
inconsistencies have been noted between the federal and state guidelines. The LHD uses 
the guidelines set forth by the Michigan CLPPP.  
The differences between the retesting recommendations can be noted in Tables 3 
and 4. Considerable differences lie within the retesting of children who have a blood lead 
level of 10 mcg/dL or higher. As noted in Tables 3 and 4, the CDC (2018) encourages a 
more rapid than the MDHHS (2017a) response to children with levels at 10-44 mcg/dL 
and those with a level of > 60 mcg/dL. The longer a child is burdened with the lead, the 
more significant the potential for long-term, damaging effects (CDC, 2017b). Although 
48 hours may not appear as a significant difference for retesting, there is no known safe 
level of lead exposure and time is critical (CDC, 2017b). This is another area of blood 








CDC Recommendations for Obtaining a Confirmatory Venous Sample 
 
Blood lead level 
 
            Time to confirmation testing 
 
< 5-9 mcg/dL  1-3 months  
10-44 mcg/dL  1 week-1month*  
45-59 mcg/dL  48 hours  
60-69 mcg/dL 
>70 mcg/dL 
 24 hours 
Urgently as an emergency test 
 
*The higher the capillary test result, the more urgent the need for confirmatory venous 
testing. 
 
Note. Adapted from the Centers for Disease Control and Prevention (2018). 
Table 4 
 
Michigan CLPPP Recommendations for Obtaining a Confirmatory Venous Sample 
 
Blood lead level 
 
Time to confirmation testing 
 
5-14 mcg/dL                              1-3 months 
15-44 mcg/dL   Within 4 weeks 
45+ mcg/dL                          Within 48 hours 
 
Note. Adapted from Michigan Department of Health & Human Services (2017a). 
Documentation 
Documentation of blood lead testing within the LHD involves multiple processes. 
Clerical staff collect and complete patient information necessary for admission to the 
clinic; this is a combination of paper and electronic records. Nursing staff assess the 
patient record within the Michigan Care Improvement Registry (MCIR), the Michigan 
statewide health database (MCIR, 2018). The Healthy Homes and Lead Prevention 
Program Surveillance System (HHLPSS) transfers records of all blood lead results 
completed in the State of Michigan into the MCIR system for access by medical care 
providers (MDHHS, 2017b). Once the patient meets with the nurse, a determination of 
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whether a blood lead test will take place is based upon the patient’s age, insurance 
coverage, prior testing, answers to the screening questionnaire, and consent from the 
guardian. If a decision to obtain a test is made, the nurse and guardian sign the agency’s 
consent form and the process begins. The LHD utilizes a point-of-care blood lead 
analyzer for test completion. Once the sample is obtained, the nurse records the patient’s 
information on the clinic testing log to include date, patient name, result of the test, 
initials of the nurse, and whether the test will be billed to Medicaid or another source. 
The clinic testing log is faxed daily to an agency clerical staff that collects all testing logs 
for the jurisdiction and reports testing activity to the HHLPSS system on a weekly basis.  
The nurses must also record the patient’s name on a separate agency laboratory 
log and indicate a blood lead test was conducted. For patients enrolled in WIC, the nurse 
must also record the results within the WIC electronic record. The LHD’s electronic 
medical record is a distinct system from WIC, and therefore requires additional 
documentation of the patient data to ensure that the agency has a record of the test and 
Medicaid billing is completed. When a result is determined to be elevated, ongoing 
documentation associated with case management ensues, which involves the use of an 
additional agency computerized log and the HHLPSS case management database.  
A minimum of three people, three paper records, and four electronic records are 
enlisted with each blood lead test. The numbers of staff involved increases if a lead result 
is elevated. The process is labor-intensive and has increased potential for documentation 
errors. The American Nurses Association (ANA) Principles for Nursing Documentation 
(2010) recommend that nurses should strive to ensure all necessary patient information is 
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documented while avoiding duplicative documentation. To enhance documentation 
procedures, nurses should participate in organizational decisions aimed at facilitating the 
development of an electronic medical record (EMR) that is compatible with other 
systems, create user-friendly and efficient means of documentation, and create linkages 
to evidence-based practice guidelines to promote up-to-date interventions (ANA, 2010). 
One of the LHD’s remote clinic locations does not have a point-of-care analyzer 
on-site. Blood lead samples are obtained at the remote site by nurses and registered 
dieticians who travel to the site for patient appointments. Frequently, the registered 
dieticians do not return to the main clinic site, and samples are transported the following 
day by a clerical staff member to the main clinic for analysis to be completed by a nurse. 
Any nurse available in the main clinic site is tasked with completing the testing process 
with the point-of-care analyzer and logging the patient information on the clinic testing 
log; however, this is where documentation of the testing process stopped. Nurses 
completing the analysis of the sample did not believe it was their responsibility to record 
the sample results within the agency electronic medical record, complete the billing 
process, or document the results in the WIC electronic record. Many results were not 
fully documented related to this gap in care and responsibilities.  
Documentation of lead testing within the LHD was an area of concern. 
Documentation duplication can serve as a source of frustration for nurses and increase 
data errors (Cowden & Johnson, 2003). The nursing staff has voiced concerns over the 
documentation processes and acknowledge that errors have been made. “I don’t know 
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how we are supposed to keep up with all of this,” (personal communication, November 
14, 2018). 
Case Management 
According to LHD policy and the Michigan CLPPP (MDHHS, 2017b), if a child 
has an elevated blood lead level of > 5 mcg/dL, case management services are to be 
provided to the child; differing significantly from the MDHHS (2018) laboratory policy 
that states any result of 4.5 to 4.9 mcg/dL is to be considered an elevated level. Case 
management activities within the State of Michigan include home visits by public health 
nursing staff to assess the child’s health, nutrition, social patterns, and developmental 
stage as well as complete a visual inspection of the home for lead hazards and provide 
education to the family (MDHHS, 2017b). All children, regardless of medical insurance 
coverage, are eligible to receive one nursing home visit; however, if a child is enrolled in 
Medicaid, up to a total of six home visits may be provided by a Registered Nurse who is 
CLPPP trained and the LHD will be reimbursed $201.28 per home visit with funding 
through Children’s Special Health Care Services Medicaid Elevated Blood Lead Case 
management program (MDHHS, 2017b). The only additional service available for 
children who are not enrolled in Medicaid is a referral to a primary care provider 
(MDHHS, 2017b).  
Established LHD procedures referred nursing staff to the Michigan CLPPP case 
management website for guidance, although no direct training is conducted. The LHD 
procedures also refer to use of the Healthy Housing Lead Poisoning Surveillance System 
(HHLPSS) upon completion of case management home visits. According to the HHLPSS 
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website, the intent of the program is to track screening of children for lead toxicity, 
identify confirmed elevated cases, medical management of case, track non-paint lead 
hazards, investigate and provide abatement for lead hazards and provide a centralized, 
state-based repository for information (U.S. Department of Health & Human Services, 
2016a). Unfortunately, there was no training process for HHLPSS documented within the 
LHD and access to the system requires approval from HHLPSS administrators (MDHHS, 
2017b). Ensuring that nurses responsible for case management activities receive training 
and have access to the HHLPSS system may promote consistent documentation practices. 
Within the CLPPP case management guidelines, it was noted that the HHLPSS 
system has a limited ability to export data; therefore, LHD’s may need to utilize an 
electronic medical record to capture key activities for data tracking (MDHHS, 2017b). 
The LHD did not employ an EMR capable of this process nor did the nursing staff use 
the agency’s EMR for anything related to blood lead other than billing Medicaid for 
provided services. The LHD lead coordinator was concurrently piloting an organization- 
specific electronic document to track activities associated with lead follow up and case 
management activities. A process of multiple systems is cumbersome and increases the 
risk of documentation errors (Cowden & Johnson, 2003).  
Not every child identified with an elevated blood lead level will have received 
testing from the LHD. Private providers are available throughout the LHD’s jurisdiction 
to provide lead screening to patients. If, however, a private provider detects an elevated 
level, a referral for follow-up services provided to the LHD (AAP, 2013). The LHD will 
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conduct case management services for that child as if testing had occurred within the 
agency.  
The LHD does not employ a certified environmental lead inspector on staff; 
therefore, any environmental investigations are handled by HHLPSS staff MDHHS, 
2017b). The HHLPSS environmental inspections occur based on the timeline depicted in 
Table 5.  
Providing training to nurses that conduct elevated blood lead follow up is vital to 
the provision of efficient and effective patient care (MDHHS, 2017b). Maintaining 
available resources in one common area is a central need to provide consistent services. 




HHLPSS Environmental Investigation Timeline 
 
Blood Lead Result 
 
            Inspection Timeframe 
 
< 5 mcg/dL  HHLPPS schedule permitting  
5-10 mcg/dL  2 weeks  
10- < 45 mcg/dL  1 week  




Note. Adapted from Michigan Department of Health & Human Services (2017b). 
 
Limitations to Findings 
Several guidelines from state and federal resources were discovered to be 
inconsistent and out of date. Collection and follow-up guidelines for healthcare providers 
on the MDHHS website were dated 2010; multiple updates to the collection, testing, and 
follow-up procedures have occurred since this time (CDC, 2017b; MDHHS, 2017a; 
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MDHHS, 2017b). Inconsistent guidelines may lead to confusion and misunderstanding of 
information.  
No members of the DNP project team had knowledge of the MDHHS Childhood 
Lead Poisoning Prevention Program website before beginning the analysis process. This 
website houses information regarding blood lead activities and case management 
procedures at the state level (MDHHS, 2017b). Each member of the project team has 
performed case management for children with elevated blood lead levels, and this 
website would have been valuable to enhancing care provided to these children. 
Implications of Findings 
No level of blood lead is known to be safe (CDC, 2017b). Reliable identification 
of lead-burdened children can be accomplished when evidence-based testing procedures 
are applied consistently (AAP, 2017). If the results of the DNP project and the CPG are 
implemented, lead-burdened children within the LHD jurisdiction will have the 
opportunity to be identified and treated. Cognitive and behavioral impairments resulting 
from lead toxicity may be circumvented with appropriate testing practices (AAP, 2017). 
Through focused assessments and education provided by public health nurses, 
community knowledge regarding blood lead toxicity may be increased (Polivka et al., 
2009).  
As the CPG is considered, education of the nursing staff has the potential to 
expand. Offering consistent training practices was found to increase the number of blood 
lead specimens collected during a research study by Polivka et al. (2009). The possibility 
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of replicating this increase in testing numbers within the LHD may be achieved with 
consistent practices.  
On an institutional level, the CPG may promote and support the inclusion of 
evidence-based practices during the development of future LHD procedures. The 
organization historically utilized a top-down approach to procedural implementation. The 
DNP project team assisted throughout the project development process and voiced an 
increased understanding related to evidence-based practices.  
Research efforts identified the discrepancy of testing result levels. Existing LHD 
procedures called for the initiation of follow up procedures for a blood lead result of > 5 
mcg/dL. Established LHD policies did not reference the process of rounding retrieved 
results of 4.5 to 4.9 mcg/dL to a value of 5.0 mcg/dL and considering these values to be 
an elevated result requiring venous blood draw for confirmation. The rounding of results 
would be a significant change in practice for the LHD. 
The medical director of the LHD is also responsible for two other jurisdictions, 
resulting in a total coverage area of 19 counties. The administrative teams representing 
the three health jurisdictions meet regularly to discuss procedures that are conducted 
concurrently under the supervision of the medical director. If acceptable to the LHD, this 
clinical practice guideline also has the potential to be adopted in other health 
departments, expanding its potential to display a positive impact on social change. 
Recommendations 
A clinical practice guideline has been developed with consideration of the 
presented information. The clinical practice guideline is identified as Appendix D of this 
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document. The clinical practice guideline strives to incorporate evidence retrieved from 
the systematic review of evidence and optimize patient care within the LHD. Information 
regarding a developed clinical practice guideline was collected from five expert panelists 
using the AGREE II instrument for evaluation purposes. The retrieved information 
substantiated the validity and intent of the clinical practice guideline as demonstrated in 
the presented results. 
Discussion of Evaluation 
Evaluation of the clinical practice guideline was conducted using the AGREE II 
instrument by blood lead testing experts. Ten local experts were invited to participate in 
the review process, and five responded with completed AGREE II instruments, indicating 
their acceptance to participate. All invited and participating evaluators had blood lead 
testing experience of greater than two years, currently conduct blood lead testing, and 
have case management experience related to elevated lead levels. The AGREE II 
instrument uses a seven-point Likert-type scale ranging from a score of 1 (strongly 
disagree) to 7 (strongly agree). In scoring the appraisal results, a score of four and above 
indicated agreement with the domain item while a score of three or below indicated 
disagreement with the domain item. Table 6 represents the summarized data of the 
AGREE II Instrument results. Detailed results of the AGREE II instrument domains are 




AGREE II Summarized Data 
        AGREE II Domain % of Appraiser agreement 
Domain 1: Scope and Purpose 100% 
Domain 2: Stakeholder Involvement 96.6% 
Domain 3: Rigor and Development 99.2% 
Domain 4: Clarity of Presentation 97.8% 
Domain 5: Applicability 99.2% 
Domain 6: Editorial Independence 100% 
Overall Guideline Assessment 96.4% 
Recommendation of guidelines for use 100% Yes, without modifications 
 
Domain 1 of the AGREE II instrument focuses on addressing the scope and 
purpose of the clinical practice guideline (CPG) (Brouwers et al., 2010). Within Domain 
1, all appraisers documented full support of the CPG with one appraiser noting that 
established testing procedures within their agency were not as thorough as the CPG. 
Domain 2, Stakeholder Involvement, received an overall score of 96.6% with appraiser’s 
remarks being unsure of exactly who was participating on the DNP project team. 
Comments were also received regarding that although the CPG has a nursing focus, other 
health care providers could also utilize it.  
The rigor of development is assessed in Domain 3 (see Brouwers et al., 2010) and 
received a score of 99.2%. In this domain, appraisers offered praise for the strength of 
evidence retrieved within the CPG and noted areas of missing information from 
established procedures within their place of employment. One appraiser did share a lack 
of support for testing non-Medicaid enrolled children for blood lead exposure. Domain 4 
explored the clarity of presentation (see Brouwers et al., 2010) and scored 97.8% from 
the appraiser; no comments were provided in this domain. 
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The topic of CPG applicability was addressed within Domain 5 (see Brouwers et 
al., 2010). An appraisal score of 99.2% was achieved with one evaluator noting are many 
barriers to regular use of evidence-based practices within their practicing organization. 
Editorial independence was presented in Domain 6 (see Brouwers et al., 2010) and 
attained a 100% score. Item 23 within Domain 6 was deemed to be not applicable (NA) 
as there were no competing interests noted between the CPG development group 
members. The final area of the AGREE II instrument is the overall guideline assessment 
(see Brouwers et al., 2010), where 100% of the appraisers recommended the use of the 
CPG without modifications. 
Contribution of the Doctoral Project Team 
The DNP project team consisted of two public health nurses and a nurse manager. 
The nurse manager was assigned to the coordinator role for blood lead management 
within the jurisdiction. The team members played an intricate role throughout the 
development process. The members were eager to provide information regarding current 
practices, engage in discussions of literature findings, and offer considerations of 
alternative approaches to processes within the agency. Collaborative work occurred via 
in-person meetings and email correspondence. 
The team members had a demanding schedule with regularly assigned duties and 
time spent in collaboration with the student was appreciated. The project team was 
enthusiastic about a consistent approach to lead testing and the potential of LHD 
procedural development utilizing the clinical practice guideline. “A policy that was 
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correct and we could follow would be so valuable,” (personal communication, November 
14, 2018). 
The project team offered various scenarios of blood lead testing practices being 
conducted but not part of a written policy. An example of this included the analyzing of 
blood samples obtained by a registered dietitian from children in a remote clinic and 
returned to the primary clinic the following day. One member of the team was 
completing all documentation related to the testing, while the other member completed 
the specimen analysis but did not document results in the patient record. Another area 
involved the reporting of results 4.5 to 4.9 mcg/dL. According to the nurse manager, one 
LHD clinic is rounding results to 5 mcg/dL but the remaining five sites are not, and the 
rounding of results is not included in the established LHD policies.  
The blood lead coordinator forecasted incorporation of the clinical practice 
guideline into the health department processes following completion of the DNP project. 
There is potential to expand incorporation of the clinical practice guideline usage to other 
surrounding health departments; support from the LHD blood lead coordinator will assist 
in the potential of this developing. It is the intent of the project to be incorporated within 
the LHD, thereby supporting the continued use of research and evidence-based practices 
in future procedural developments. 
Strengths and Limitations 
Throughout the project, it appeared that some LHD nursing staff value 
establishing consistent practices through incorporating evidence from scholarly resources 
whereas other members accept current practices are sufficient. Staff that were not fully 
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supportive of the project did not belittle the attempts of the DNP team but voiced 
statements of “that is too much work and what we are doing now is fine,” (personal 
communication, July 23, 2018). Fortunately, the blood lead coordinator, administrative 
members, and other nursing staff were supportive of the effort.  
A limitation of the project is the lack of uniformity related to blood lead testing on 
a broad scale; many recommendations exist but identified consistencies were minimal. A 
noteworthy example of a consistent and effective approach to blood lead testing can be 
found in Allegheny County, Pennsylvania. Leaders within the community noted that 
blood lead testing levels were low and action was taken to improve testing rates 
(Allegheny County Health Department [ACHD], 2018a). Effective January 1, 2018, all 
children residing within Allegheny County are required to be tested for blood lead at 9-12 
and 24 months of age (ACHD, 2018a). Children are required to have lead testing 
completed prior to kindergarten entry (ACHD, 2018b). The cost of testing for those 
without health insurance coverage is paid for by the Allegheny County Health 
Department (ACHD, 2018b). In 2009, 10,838 children less than 72 months of age were 
screened within Allegheny County; since enacting the testing requirement, the county is 
on pace to test more than 23,000 unduplicated children in 2018 (ACHD, 2018b). The 
establishment of a school-entry requirement was a significant achievement toward 
identification of lead burdened children. Although the LHD did not have a mandatory 
regulation in place, the example of Allegheny County offers resources and data in support 
of developing widespread, consistent practices.  
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Acceptance of the clinical practice guideline for use within the LHD would 
promote up-to-date and consistent nursing actions in the provision of blood lead testing. 
Prior to the DNP project, minimal attention had been given to update the testing process 
and care was provided status quo; however, this project may be a stimulus for moving 
established practices forward. Enactment of the clinical practice guideline may facilitate 
advanced nursing care, improve health outcomes of children, and decrease societal 
burdens related to lead toxicity. If support is received, the clinical practice guideline 
could be expanded to other health department jurisdictions. 
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Section 5: Dissemination Plan 
Throughout this project, I worked closely with nurses from the project site. 
According to Melnyk (2013), the DNP scholarly project should focus on translating 
“research findings into clinical practice or policy to positively influence health care and 
patient and policy outcomes” (p. 444). The focus of the current scholarly project was to 
improve the blood lead testing practices in the LHD.  
Sharing the developed clinical practice guideline with the organization may 
increase the likelihood of the LHD adopting evidence-based practices and improved 
patient care practices regarding the blood lead testing process. Dissemination of the 
clinical practice guideline will begin with the nursing director and blood lead coordinator. 
The agency has a history of implementing procedures with a top-down approach; 
however, staff inclusion throughout the development of the clinical practice guideline 
may assist in its acceptance within the organization. 
The agency supporting the development of the clinical practice guideline is a 
rural, jurisdictional public health department. The medical director of the LHD has a 
leadership role in two additional jurisdictional health departments, totaling 19 counties of 
responsibility. This multiagency relationship may increase the likelihood of adoption of 
the practice guideline throughout the region. Although the characteristics of the LHD are 
specific, any health care provider who performs blood lead testing could benefit from the 
information contained in the practice guideline. Empowering nurses with resources and 
evidence-based information to support improved patient care practices is appropriate in 
any situation (White et al., 2016). 
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I intend to offer the project for review and consideration to the American Public 
Health Association, Public Health Nursing journal, the Journal of Community & Public 
Health Nursing, the Journal of Environmental and Public Health, and BMC Public 
Health. If approved for publication, the DNP project would be disseminated to a broad 
nursing base. In addition, I will develop a poster presentation to share with professional 
audiences. Potential presentation sites include the Lilly Conference for Evidence-Based 
Teaching & Learning and the Michigan Chapter of the American Nurses Association 
Annual Conference. Seeking permission to share the information during Michigan 
Childhood Lead Poisoning Prevention Program training sessions would also expand the 
reach of the clinical practice guideline information. 
Analysis of Self 
The DNP scholarly project has broadened my knowledge base regarding 
evidence-based practices and the importance of using research to guide policy 
development. I have worked in public health settings and have witnessed the lack of staff 
support in the proactive development of organizational procedures. Limited staffing 
levels and a lack of administrative understanding have resulted in reactionary processes 
that have been fueled by requirements of regulatory agencies. Engaging LHD members 
throughout the project development and sharing the process of identifying nursing 
research expanded not only my knowledge but also the knowledge of DNP project team 
members. The project team members now have resources available to support future 
procedural development projects.  
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The American Association of Colleges of Nursing (AACN, 2006) Essentials of 
Doctoral Education for Advanced Nursing Practice shares the importance of DNP 
graduates to be skilled in both providing patient care and understanding the 
organizational arena in which they are working. The current project provided me the 
opportunity to identify issues negatively impacting patient care, to create an evidence-
based clinical practice guideline that can provide the basis for effective and efficient 
future testing procedures in the LHD, and to have an impact on patient care resulting in 
positive social change.  
As a nurse, I did not previously seek evidence-based information; however, the 
DNP project has refocused my practices. I grew in understanding the importance of 
seeking information rather than accepting the status quo. As a DNP scholar, I have made 
a personal commitment to lifelong learning and striving to be a change agent for my 
profession. I am no longer complacent with existing conditions but seek improvements in 
the nursing practice and patient care.  
The employment of principles associated with finance, business, and health 
policies to implement effective practice initiatives is an essential characteristic of DNP-
prepared nurses (AACN, 2006). As a project manager, I have a great deal to learn. My 
abilities as a practitioner and scholar increased during this project, but I have work to do 
on my management skills. Having a stronger background in the established practices of 
the LHD may have assisted in my efforts; however, in the future I will likely face similar 
circumstances. The knowledge that I have gained throughout this process has provided 
me with the direction needed to be a competent project manager. Using those skills in 
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future endeavors will help me hone my project manager abilities. As these skills develop, 
so will my ability to be a change agent for the nursing profession. 
As the DNP project comes to completion, I am excited for what the future holds. I 
have new confidence in my abilities and hope for improved nursing practices in the LHD. 
I now understand the commitment it takes to develop a practice guideline in a thorough 
and supported manner versus responding to a regulatory condition. It has been a long 
journey with a variety of professional barriers requiring persistence and perseverance. 
Gaining the trust and respect of members of the LHD was more difficult than anticipated, 
but through communication, relationships and understanding were achieved. The project 
has facilitated ongoing relations between the LHD and me, and have opened the door for 
future collaborations to improving patient care. 
Summary 
The importance of blood lead testing cannot be underestimated. With no known 
safe level of blood lead, accurate and consistent testing practices are crucial to the 
identification of lead-burdened children (CDC, 2017b). The established blood lead testing 
procedures in the DNP project site lacked evidence-based practices and consistent 
implementation throughout the jurisdiction. In this project, I sought to develop a clinical 
practice guideline to be incorporated in the daily operations of the local health 
department and potentially in other blood lead testing agencies. All relevant information 
was used in the development of the clinical practice guideline to improve nursing practice 
related to blood lead testing. One lead-burdened child is too many. The developed 
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Appendix A: Letter of Invitation to Participate in the Review of a Doctoral Project 
My name is Becky Johnson-Himes and I am a graduate student in the Doctor of 
Nursing Practice program at Walden University. I am developing a clinical practice 
guideline for blood lead testing of preschool aged children in a public health department 
setting. You have been identified as an expert in the field of blood lead testing based on 
years of work within a public health setting and history of conducting blood lead testing. 
As an expert, your knowledge of blood lead testing will be a valuable resource 
toward ensuring the clinical practice guideline is evidence-based and peer reviewed. You 
are being asked to voluntarily review the developed clinical practice guideline, evaluate 
the guideline using the AGREE II instrument, and provide any comments you deem 
necessary toward improvement of the process. Once all participants have submitted their 
review, the information will be analyzed, and results shared with the agencies 
administrative staff. It is at the discretion of the agencies administrative staff as to 
whether or not the clinical practice guideline will be implemented within the agency.  
At no time will your personal information or responses to the AGREE II 
instrument be shared with anyone. Please see the enclosed Disclosure to Expert Panelist 
Form For Anonymous Questionnaires for further information regarding guidelines of this 
project. 
Thank you for your considered participation in the review of a clinical practice 
guideline that has the potential to improve nursing processes surrounding the blood lead 
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Appendix C: Disclosure to Expert Panelist Form for Anonymous Questionnaires 
To be given to an expert panelist prior to collecting questionnaire responses—note that 
obtaining a “consent signature” is not appropriate for this type of questionnaire and 
providing respondents with anonymity is required. 
Disclosure to Expert Panelist: 
You are invited to take part in an expert panelist questionnaire for the doctoral project 
that I am conducting. 
Questionnaire Procedures: 
If you agree to take part, I will be asking you to provide your responses anonymously, to 
help reduce bias and any sort of pressure to respond a certain way. Panelists’ 
questionnaire responses will be analyzed as part of my doctoral project, along with any 
archival data, reports, and documents that the organization’s leadership deems fit to 
share. If the revisions from the panelists’ feedback are extensive, I might repeat the 
anonymous questionnaire process with the panel of experts again. 
Voluntary Nature of the Project: 
This project is voluntary. If you decide to join the project now, you can still change your 
mind later. 
Risks and Benefits of Being in the Project: 
Being in this project would not pose any risks beyond those of typical daily professional 





I might know that you completed a questionnaire, but I will not know who provided 
which responses. Any reports, presentations, or publications related to this study will 
share general patterns from the data, without sharing the identities of individual 
respondents or partner organization(s). The questionnaire data will be kept for a period of 
at least 5 years, as required by my university. 
Contacts and Questions: 
If you want to talk privately about your rights in relation to this project, you can call my 
university’s Advocate via the phone number 612-312-1210. Walden University’s ethics 
approval number for this study is (Student will need to complete Form A in order to 
obtain an ethics approval number). 
Before you start the questionnaire, please share any questions or concerns you might 
have. 





Appendix D: Clinical Practice Guideline for Blood Lead Testing Within a Local Health 
Department 
Overview 
 Obtainment of a blood sample is necessary to identify lead toxicity (American 
Academy of Pediatrics [AAP], 2013). The local health department utilizes capillary 
screening and a point-of-care analyzer to assess the blood lead level of children. As one 
of the few interventions available to screen for lead burden within children, it is 
imperative that consistent, evidence-based practices are employed during the sampling 
process (AAP, 2013). Local health department (LHD) procedures must be applied in a 
reliable manner by appropriately trained staff to be effective and efficient in the testing 
process. Information obtained from a systematic review of literature, national, state, and 
local resources was applied in the development of this clinical practice guideline. No 
funding was received to support the development of this clinical practice guideline.   
 There is no identified safe level of lead to be housed in the human body (Centers 
for Disease Control and Prevention [CDC], 2017b). In various amount, lead exposure 
occurs worldwide (World Health Organization, 2018). On a global level, it is estimated 
by the World Health Organization (2018) that lead exposure resulted in 540,000 deaths 
and 13.9 million lost years of healthy life during 2016. It is known that exposed children 
absorb lead up to 50% more than adults (Michigan Department of Health and Human 
Services [MDHHS], 2017) and that detrimental effects of lead toxicity impact nearly 
every system of the body (CDC, 2017b). Effects of lead burden include impairment of the 
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nervous system, altered cognitive functioning, hypertension, anemia, the toxicity of 
reproductive organs, and impaired kidney function (World Health Organization, 2018).  
 Early identification of elevated blood lead levels provides the opportunity for 
early interventions, resulting in improved cognitive and behavioral functioning (State of 
Michigan, 2016). Early interventions positively impact child health outcomes and societal 
considerations. It has been estimated by the State of Michigan (2016) that $270 million in 
decreased earnings, health care costs, special education services, and increased levels of 
delinquency were related to lead burden in 2014. Additionally, 10% of juvenile crimes, 
an annual rate of $1.33 million in incarnation fees, and $64.6 million in costs associated 
with adult crimes have been linked to lead exposure in Michigan (Ecology Center, 2016).   
 Children at a higher risk of lead exposure include those living in poverty, 
members of racial-ethnic minority groups, those living in or visiting older homes, those 
who have guardians who are exposed to lead at work, and those who are recent 
immigrants (CDC, 2017). According to the Kids Count Data Center (2018), 14.9% of 
children under the age of 5 belong to a racial-ethnic minority group, and 25.7% of 
children are living in poverty in the boundaries of the LHD.  Also, within the LHD 
jurisdiction, 55.4% of the housing units were constructed prior to 1979 (U.S. Department 
of Commerce, n.d.). For homes that were built before 1978, it is important for families to 
be aware of the dangers of lead dust and to consider the services of a certified renovator 
knowledgeable in decreasing the exposure of lead dust during renovations and repairs 
(Allegheny County Health Department, 2018a).   
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 Current Medicaid regulations require the testing of all enrolled children at 12 and 
24 months of age (MDHHS, 2017a). However, only 72% of children 1 or 2 years of age 
living within the jurisdiction were tested in 2015 (MDHHS, 2017c). To promote effective 
and consistent blood sample collection that will accurately identify lead toxicity, 
evidence-based practices must be employed throughout the development and 
implementation of clinic procedures. An annual review of jurisdictional testing rates and 
blood lead testing research may promote the continued use of evidence-based practices, 
thereby supporting safe and effective patient care.   
Assessment Practices 
 Although it is recommended by the American Academy of Pediatrics (2017) and 
Centers for Disease Control and Prevention (2017a) to conduct screening questionnaires 
related to blood lead testing, the questionnaires have been shown to lack validity. Verbal 
interviewing of guardians provides the opportunity to identify circumstances that may 
place the child at a higher risk of lead exposure. Use of a self-completed questionnaire 
has been shown to generate different information than what is gathered during a personal 
interview (Bergmann, Jacobs, Hoffmann, & Boeing, 2004).  A 2016 study by Nicholson 
and Cleeton revealed a risk assessment questionnaire sensitivity of 26.3% and specificity 
of 72.2% in predicting blood levels greater than 2 mcg/dL. The U.S. Preventive Services 
Task Force (2006) noted a specificity of blood lead questionnaires as ranging from 32% 
to 75% in the identification of elevated lead levels. Basing the decision to test a child 
solely on a screening questionnaire may increase the risk of a lead-burdened child being 
unidentified. Nurse engagement with guardians is an essential step toward assessing 
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understanding of lead exposure, associated dangers, and establishing guardian 
understanding of testing indications.   
Testing Guidelines 
 National, state, and local age recommendations for testing are consistent at 12 and 
24 months of age (CDC, 2017a; MDHHS, 2017b). Children enrolled in Medicaid are 
required to be tested at these ages (MDHHS, 2017b). Children receiving services through 
the supplemental food program Women, Infants, and Children (WIC) are also mandated 
under federal guidelines to receive blood lead testing at 12 and 24 months of age, 
regardless of Medicaid enrollment (State of Michigan, 2018b). A household income of 
below 185% of the Federal Poverty Guidelines, Medicaid enrolled, or receiving food 
stamps determine a child’s eligibility for the WIC program (State of Michigan, 2018b).  
 A discrepancy of the location to obtain testing exists for children who are not 
enrolled in Medicaid. Michigan is not a state that requires private insurance companies to 
reimburse for blood lead testing, nor is the LHD required to test those children without 
Medicaid coverage (see State of Michigan, 2018b). When considering the identification 
of lead-burdened children and the at-risk category of living in poverty (CDC, 2017b), all 
children receiving services within the WIC program should be tested. Advocating for 
reimbursement of blood lead testing from private insurance providers may promote 
further testing of at-risk children, facilitate early intervention services for identified 
children, and decrease societal costs associated with lead burden.  
 Allegheny County, Pennsylvania implemented a successful approach to achieving 
widespread blood lead testing within a community. In response to a 31% testing rate for 
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children under the age of 72 months, Allegheny County enacted a regulation mandating 
all children be lead tested at 9-12 and 24 months of age (Allegheny County Health 
Department, 2018b). The regulation went into effect January 1, 2018, and has yielded an 
increase from 10,838 children tested in 2009 to an estimated greater than 23,000 that will 
be tested in 2018 (Allegheny County Health Department, 2018a). Advocacy efforts by 
healthcare providers and community leaders led to this positive social change.  
 Collaborating with partner agencies to offset the costs associated with testing may 
offer an opportunity to increase the number of children tested who are identified as being 
at-risk but who have private health insurance. Head Start agencies are federally mandated 
to have enrolled children tested between the ages of 36 and 72 months (U.S. Department 
of Health & Human Services, 2016b). Head Start is willing to reimburse the LHD for 
costs associated with blood lead testing for any enrolled child that is not receiving 
Medicaid coverage (personal communication, May 2, 2018). Community partnerships 
may have the potential to expand testing services.   
Training Opportunity  
 A training program for nursing staff should be developed and administered within 
the LHD to promote consistent practices. Capillary blood lead specimen collection has a 
potential to become contaminated from the environment when proper technique is not 
followed (AAP, 2013). Although identified resources from the CDC, Michigan 
Department of Health and Human Services, and Magellan Diagnostics are referenced 
established LHD policies, there is no record of a consistently implemented training 
program. Each of the above resources offers specific information valuable to the method 
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of obtaining a blood lead sample, but none offer the complete process. Documentation 
and verification of completing a developed training course will promote assurance of 
testing process being completed appropriately.  
Reporting of Results  
 The Michigan Department of Health and Human Services Childhood Lead 
Poisoning and Prevention Program (CLPPP) has a policy in place to round blood lead 
results of 4.5 to 4.9 mcg/dL to 5.0 mcg/dL, which is considered an elevated result (State 
of Michigan, 2018a). This policy is important to incorporate into the practices of the 
LHD. A LHD policy statement of > 5 mcg/dL being an elevated results does not delineate 
the rounding of results from 4.5 to 4.9 mcg/dL up to 5 mcg/dL. Without the incorporation 
of this policy, children with a blood lead level of 4.5 to 4.9 mcg/dL will go without 
identification and necessary follow up procedures related to an elevated level.  
 If an elevated level of lead is identified through capillary sampling, confirmatory 
venous testing should ensue (AAP, 2013). Variation exists in the state and federal 
recommendations of time to obtain a confirmatory test based on the result level (see 
CDC, 2018; MDHHS, 2017a). Adoption of a consistent timeframe for completing 
confirmatory testing within the LHD will aid in the uniformity of testing practices.    
Documentation  
 It is recommended by the American Nurses Association (ANA) Principles of 
Nursing Documentation (2010) that duplicative documentation should be avoided to 
minimize the risk of error. A combination of paper and multiple electronic databases 
increases the risk of documentation error exponentially. The repetition of documentation 
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is inefficient, a source for staff frustration, and has a great potential to decrease the 
integrity of the records (Cowden & Johnson, 2006). Through the collaborative efforts of 
nursing staff, clerical, administrative, billing, and internet technology staff, a process of 
efficient documentation can occur. 
Case Management  
 For a family receiving notification of a child’s elevated blood lead level, the news 
may be overwhelming. Depending on the result level, follow up procedures may begin 
immediately or require retesting in three months (see CDC, 2018; MDHHS, 2017a). 
Regardless of the timeline, a public health nurse knowledgeable in the process is vital to 
the success of the follow up process. An educated nurse will provide case management 
efforts offering instruction to the family in an on-going manner. Case management of 
elevated blood lead cases continues until the child’s blood lead level is no longer elevated 
and education of the family has been completed (MDHHS, 2017b).  
 Reimbursement of home visits made to Medicaid enrolled children is provided 
through the Michigan CLPPP (MDHHS, 2018a). Unfortunately, home visit 
reimbursement is not available for those children not enrolled in Medicaid (see MDHHS, 
2018a). Without education of the family and identification of the lead source, the toxicity 
of the child will continue. Regardless of Medicaid status, community health practices 
must provide follow-up services to the family.  
 Documentation of case management services for elevated lead cases is 
encouraged through the Healthy Housing Lead Poisoning Surveillance System 
(HHLPSS) (MDHHS, 2017a). The HHLPSS is not a required database for case 
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management practices; however, it is a statewide database that offers consistency of 
documentation (MDHHS, 2017a). Incorporating the consistent use of this state-facilitated 
database would increase the reliability of case management practices.     
Interventions 
 There is no known safe level of lead within the human body (CDC, 2017b). It has 
been established that screening is recommended for children at 12 and 24 months of age 
who are identified as being at risk for lead exposure (AAP, 2013); however, a consistent 
approach to the testing process has not been reliably established within the agency. LHD 
staff should work collaboratively to identify effective and efficient practices within the 
organization to promote early identification of lead-burdened children and increase the 
education of families related to lead toxicity. All children receiving services within the 
WIC program are at an increased risk of lead exposure based on CDC guidelines (see 
CDC 2017b) and therefore, should be screened for blood lead levels regardless of 
Medicaid enrollment status at the time of service versus referring to a different provider. 
Referring a child to receive testing from another healthcare provider is a lost opportunity 
for providing care. A lack of direction in practices and complication of documentation 
has been identified as being frustrating to staff and resulting in some children not being 
tested. Applying the information of this clinical practice guideline will enhance health 
department services for lead-burdened children, thereby improving health outcomes for 




Appendix E: AGREE II Detailed Appraisal Item Scores 
Domain 1: Scope and Purpose 
 Item 1 Item 2 Item 3 Total % Score 
Appraiser 1 7 7 7 21 100% 
Appraiser 2 7 7 7 21 100% 
Appraiser 3 7 7 7 21 100% 
Appraiser 4 7 7 7 21 100% 
Appraiser 5 7 7 7 21 100% 
Total Domain 1 35 35 35 105 100% 
 
Domain 2: Stakeholder Involvement   
  Item 4 Item 5 Item 6 Total % Score 
Appraiser 1 7 7 7 21 100% 
Appraiser 2 7 5 7 19 90.5% 
Appraiser 3 7 7 7 21 100% 
Appraiser 4 7 6 7 20 95.2% 
Appraiser 5 7 7 7 21 100% 
Total Domain 2 35 33 35 102 96.6% 
 





















Appraiser 1 7 7 7 7 7 7 7 7 56 100% 
Appraiser 2 7 7 6 7 7 7 7 7 55 98.2% 
Appraiser 3 7 7 7 7 7 7 7 7 56 100% 
Appraiser 4 7 7 7 7 7 7 7 7 56 100% 































Domain 4: Clarity of Presentation  
 Item 15 Item 16 Item 17 Total % Score 
Appraiser 1 7 7 7 21 100% 
Appraiser 2 6 7 7 20 95.2% 
Appraiser 3 7 7 7 21 100% 
Appraiser 4 7 7 7 21 100% 
Appraiser 5 7 6 7 20 95.2% 
Total Domain 3 34 34 35 103 97.8% 
 
Domain 5: Applicability  
 Item 18 Item 19 Item 20 Item 21 Total % Score 
Appraiser 1 7 7 7 7 28 100% 
Appraiser 2 6 7 7 7 27 100% 
Appraiser 3 7 7 7 7 28 100% 
Appraiser 4 7 7 7 7 28 100% 
Appraiser 5 7 7 7 7 28 100% 
Total Domain 5 34 35 35 35 139 99.2% 
 
Domain 6: Editorial Independence   
 Item 22 Item 23 Total % Score 
Appraiser 1 7 NA 7 100% 
Appraiser 2 7 NA 7 100% 
Appraiser 3 7 NA 7 100% 
Appraiser 4 7 NA 7 100% 
Appraiser 5 7 NA 7 100% 












Overall Guideline Assessment 
1. Rate the overall quality of this 
guideline. 
   
 Score Total % Score 
Appraiser 1 7 7 100% 
Appraiser 2 6 6 85.7% 
Appraiser 3 7 7 100% 
Appraiser 4 7 7 100% 
Appraiser 5 7 7 100% 
        Total Score for Question 1 34 34 96.4% 
2. I would recommend this guideline 
for use.  
   
 Yes Yes, with modifications No 
Appraiser 1 Yes   
Appraiser 2 Yes   
Appraiser 3 Yes   
Appraiser 4 Yes   
Appraiser 5 Yes   
        Total Number of   
        Recommendations 
 
100% 
  
 
